Treatment of Candida Glabrata Infections

Introduction to Candida Glabrata

The Centers for Disease Control and Prevention recommends against using tioconazole vaginal therapy for Candida glabrata infections, as this non-albicans species demonstrates reduced susceptibility to standard azole antifungals including tioconazole 1, 2
C. glabrata accounts for 10-20% of recurrent vulvovaginal candidiasis cases and requires alternative treatment strategies beyond conventional azole therapy 1
The organism does not form pseudohyphae or hyphae, making microscopic diagnosis more challenging and requiring culture confirmation 1

The American College of Obstetricians and Gynecologists recommends boric acid 600 mg in gelatin capsule intravaginally daily for 14 days as the preferred first-line treatment for C. glabrata vaginitis, achieving clinical and mycologic success in 64-71% of symptomatic women 2
Topical flucytosine cream administered nightly for 14 days achieves successful outcomes in 90% of women whose infections failed to respond to boric acid and azole therapy 2
Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream for 14 days is effective for refractory cases 2

The Centers for Disease Control and Prevention advises against using standard short-course azole therapy (including tioconazole single-dose or 3-day regimens) for confirmed C. glabrata infections, as these will fail in the majority of cases 1
Obtain vaginal cultures in women with recurrent vulvovaginal candidiasis to identify non-albicans species, as microscopy alone may miss C. glabrata 1